Cargando…
Dynamics of central and peripheral immunomodulation in a murine glioma model
BACKGROUND: Immunosuppression by gliomas contributes to tumor progression and treatment resistance. It is not known when immunosuppression occurs during tumor development but it likely involves cross-talk among tumor cells, tumor-associated macrophages and microglia (TAMs), and peripheral as well as...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654428/ https://www.ncbi.nlm.nih.gov/pubmed/19226468 http://dx.doi.org/10.1186/1471-2172-10-11 |
_version_ | 1782165359067922432 |
---|---|
author | Kennedy, Benjamin C Maier, Lisa M D'Amico, Randy Mandigo, Christopher E Fontana, Elizabeth J Waziri, Allen Assanah, Marcela C Canoll, Peter Anderson, Richard CE Anderson, David E Bruce, Jeffrey N |
author_facet | Kennedy, Benjamin C Maier, Lisa M D'Amico, Randy Mandigo, Christopher E Fontana, Elizabeth J Waziri, Allen Assanah, Marcela C Canoll, Peter Anderson, Richard CE Anderson, David E Bruce, Jeffrey N |
author_sort | Kennedy, Benjamin C |
collection | PubMed |
description | BACKGROUND: Immunosuppression by gliomas contributes to tumor progression and treatment resistance. It is not known when immunosuppression occurs during tumor development but it likely involves cross-talk among tumor cells, tumor-associated macrophages and microglia (TAMs), and peripheral as well as tumor-infiltrating lymphocytes (TILs). RESULTS: We have performed a kinetic study of this immunomodulation, assessing the dynamics of immune infiltration and function, within the central nervous system (CNS) and peripherally. PDGF-driven murine glioma cells were injected into the white matter of 13 mice. Four mice were sacrificed 13 days post-injection (dpi), four mice at 26 dpi, and five mice at 40 dpi. Using multiparameter flow cytometry, splenic T cells were assessed for FoxP3 expression to identify regulatory T cells (Tregs) and production of IFN-γ and IL-10 after stimulation with PMA/ionomycin; within the CNS, CD4(+ )TILs were quantified, and TAMs were quantified and assessed for TNF-α and IL-10 production after stimulation with LPS. Peripheral changes associated with tumor development were noted prior to effects within the CNS. The percentage of FoxP3(+ )regulatory T cells (Tregs) increased by day 26, with elevated frequencies throughout the duration of the study. This early increase in Tregs was paralleled by an increase in IL-10 production from Tregs. At the final time points examined (tumor morbidity or 40 dpi), there was an increase in the frequency of TAMs with decreased capacity to secrete TNF-α. An increase in TIL frequency was also observed at these final time points. CONCLUSION: These data provide insight into the kinetics of the immunosuppressive state associated with tumor growth in a murine model of human gliomas. Functional impairment of TAMs occurs relatively late in the course of GBM tumor growth, potentially providing a window of opportunity for therapeutic strategies directed towards preventing their functional impairment. |
format | Text |
id | pubmed-2654428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26544282009-03-12 Dynamics of central and peripheral immunomodulation in a murine glioma model Kennedy, Benjamin C Maier, Lisa M D'Amico, Randy Mandigo, Christopher E Fontana, Elizabeth J Waziri, Allen Assanah, Marcela C Canoll, Peter Anderson, Richard CE Anderson, David E Bruce, Jeffrey N BMC Immunol Research Article BACKGROUND: Immunosuppression by gliomas contributes to tumor progression and treatment resistance. It is not known when immunosuppression occurs during tumor development but it likely involves cross-talk among tumor cells, tumor-associated macrophages and microglia (TAMs), and peripheral as well as tumor-infiltrating lymphocytes (TILs). RESULTS: We have performed a kinetic study of this immunomodulation, assessing the dynamics of immune infiltration and function, within the central nervous system (CNS) and peripherally. PDGF-driven murine glioma cells were injected into the white matter of 13 mice. Four mice were sacrificed 13 days post-injection (dpi), four mice at 26 dpi, and five mice at 40 dpi. Using multiparameter flow cytometry, splenic T cells were assessed for FoxP3 expression to identify regulatory T cells (Tregs) and production of IFN-γ and IL-10 after stimulation with PMA/ionomycin; within the CNS, CD4(+ )TILs were quantified, and TAMs were quantified and assessed for TNF-α and IL-10 production after stimulation with LPS. Peripheral changes associated with tumor development were noted prior to effects within the CNS. The percentage of FoxP3(+ )regulatory T cells (Tregs) increased by day 26, with elevated frequencies throughout the duration of the study. This early increase in Tregs was paralleled by an increase in IL-10 production from Tregs. At the final time points examined (tumor morbidity or 40 dpi), there was an increase in the frequency of TAMs with decreased capacity to secrete TNF-α. An increase in TIL frequency was also observed at these final time points. CONCLUSION: These data provide insight into the kinetics of the immunosuppressive state associated with tumor growth in a murine model of human gliomas. Functional impairment of TAMs occurs relatively late in the course of GBM tumor growth, potentially providing a window of opportunity for therapeutic strategies directed towards preventing their functional impairment. BioMed Central 2009-02-18 /pmc/articles/PMC2654428/ /pubmed/19226468 http://dx.doi.org/10.1186/1471-2172-10-11 Text en Copyright © 2009 Kennedy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kennedy, Benjamin C Maier, Lisa M D'Amico, Randy Mandigo, Christopher E Fontana, Elizabeth J Waziri, Allen Assanah, Marcela C Canoll, Peter Anderson, Richard CE Anderson, David E Bruce, Jeffrey N Dynamics of central and peripheral immunomodulation in a murine glioma model |
title | Dynamics of central and peripheral immunomodulation in a murine glioma model |
title_full | Dynamics of central and peripheral immunomodulation in a murine glioma model |
title_fullStr | Dynamics of central and peripheral immunomodulation in a murine glioma model |
title_full_unstemmed | Dynamics of central and peripheral immunomodulation in a murine glioma model |
title_short | Dynamics of central and peripheral immunomodulation in a murine glioma model |
title_sort | dynamics of central and peripheral immunomodulation in a murine glioma model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654428/ https://www.ncbi.nlm.nih.gov/pubmed/19226468 http://dx.doi.org/10.1186/1471-2172-10-11 |
work_keys_str_mv | AT kennedybenjaminc dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT maierlisam dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT damicorandy dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT mandigochristophere dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT fontanaelizabethj dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT waziriallen dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT assanahmarcelac dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT canollpeter dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT andersonrichardce dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT andersondavide dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel AT brucejeffreyn dynamicsofcentralandperipheralimmunomodulationinamurinegliomamodel |